January 29, 2021 2:45pm EST Study has the potential to facilitate a filing for Emergency Use Authorization (EUA) SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 / / Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support Rigel s ongoing Phase 3 clinical trial to evaluate the safety and efficacy of fostamatinib in hospitalized COVID-19 patients. Fostamatinib is marketed in the U.S. as TAVALISSE
® (fostamatinib disodium hexahydrate) tablets, and is approved in the U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia (ITP).
4:11
New state data revealing town-by-town COVID-19 vaccination coverage shows that the rollout in some areas of Connecticut is happening at a faster rate than in others.
The preliminary numbers confirm what some public health experts and health equity advocates have suspected all along, which is that vulnerable and underserved communities, including Black and brown neighborhoods already suffering high infection and mortality rates, are at risk of falling through the cracks.
“If we’re going to change the way we do business and how we look at health care systems, we have to start thinking about those people who have been left behind in the past in the way of health, that they are serviced,” said state Sen. Marilyn Moore, who represents the city of Bridgeport.
Covid-19 patients who suffer cardiac arrest more likely to die: Study
February 05, 2021
×
A new study carried out by researchers in Sweden revealed that Covid-19 patients who suffer cardiac arrest are more likely to die, compared to non-Covid-19 patients.
The study, published in the European Heart Journal , stressed that this threat is nine times higher in women.
For the study, the researchers included 1946 people who suffered a cardiac arrest out of hospital and 1080 who suffered one in hospital between 1 January and 20 July.
During the pandemic phase of the study, Covid-19 was involved in at least 10 per cent of all OHCAs (Out of Hospital Cardiac Arrest) and 16 per cent of IHCAs (In-Hospital Cardiac Arrest).